RS56858B1 - Postupak proizvodnje farmaceutske kompozicije u obliku tableta sa produženim-oslobađanjem koje sadrže pirfenidon i njihova upotreba u regresiji hronične renalne insuficijencije, kapsularne kontrakture grudi i hepatičke fibroze kod ljudi - Google Patents

Postupak proizvodnje farmaceutske kompozicije u obliku tableta sa produženim-oslobađanjem koje sadrže pirfenidon i njihova upotreba u regresiji hronične renalne insuficijencije, kapsularne kontrakture grudi i hepatičke fibroze kod ljudi

Info

Publication number
RS56858B1
RS56858B1 RS20180168A RSP20180168A RS56858B1 RS 56858 B1 RS56858 B1 RS 56858B1 RS 20180168 A RS20180168 A RS 20180168A RS P20180168 A RSP20180168 A RS P20180168A RS 56858 B1 RS56858 B1 RS 56858B1
Authority
RS
Serbia
Prior art keywords
regression
humans
extended
manufacturing
pharmaceutical composition
Prior art date
Application number
RS20180168A
Other languages
English (en)
Inventor
Borunda Juan Armendariz
CASTRO José Augustin Rogelio MAGAÑA
Guadarrama Jorge Cervantes
Original Assignee
Cell Therapy And Technology S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46940567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56858(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Therapy And Technology S A De C V filed Critical Cell Therapy And Technology S A De C V
Publication of RS56858B1 publication Critical patent/RS56858B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
RS20180168A 2011-07-19 2012-07-13 Postupak proizvodnje farmaceutske kompozicije u obliku tableta sa produženim-oslobađanjem koje sadrže pirfenidon i njihova upotreba u regresiji hronične renalne insuficijencije, kapsularne kontrakture grudi i hepatičke fibroze kod ljudi RS56858B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2011007675A MX2011007675A (es) 2011-07-19 2011-07-19 Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
EP15161929.3A EP2907506B1 (en) 2011-07-19 2012-07-13 Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans

Publications (1)

Publication Number Publication Date
RS56858B1 true RS56858B1 (sr) 2018-04-30

Family

ID=46940567

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180168A RS56858B1 (sr) 2011-07-19 2012-07-13 Postupak proizvodnje farmaceutske kompozicije u obliku tableta sa produženim-oslobađanjem koje sadrže pirfenidon i njihova upotreba u regresiji hronične renalne insuficijencije, kapsularne kontrakture grudi i hepatičke fibroze kod ljudi

Country Status (34)

Country Link
US (6) US9408836B2 (sr)
EP (2) EP2735306A1 (sr)
JP (1) JP6034380B2 (sr)
KR (2) KR20160074016A (sr)
CN (2) CN103957892A (sr)
AR (1) AR087205A1 (sr)
AU (1) AU2012284627B2 (sr)
BR (1) BR112014001297B1 (sr)
CA (1) CA2842654C (sr)
CL (1) CL2014000131A1 (sr)
CO (1) CO6970587A2 (sr)
CR (1) CR20140019A (sr)
CY (2) CY2200005T2 (sr)
DE (1) DE15161929T1 (sr)
DK (1) DK2907506T3 (sr)
DO (1) DOP2014000010A (sr)
EC (1) ECSP14013160A (sr)
ES (1) ES2550227T3 (sr)
HK (1) HK1208172A1 (sr)
HR (1) HRP20180183T1 (sr)
HU (1) HUE036511T2 (sr)
LT (1) LT2907506T (sr)
MX (1) MX2011007675A (sr)
NO (1) NO2907506T3 (sr)
PE (1) PE20141684A1 (sr)
PL (1) PL2907506T3 (sr)
PT (1) PT2907506T (sr)
RS (1) RS56858B1 (sr)
RU (1) RU2682177C2 (sr)
SI (1) SI2907506T1 (sr)
UA (1) UA114181C2 (sr)
UY (1) UY34190A (sr)
WO (1) WO2013012307A1 (sr)
ZA (1) ZA201400386B (sr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN105997302A (zh) * 2016-07-18 2016-10-12 青岛三帝生物科技有限公司 基于3d打印的防包膜挛缩乳房假体制作方法和乳房假体
MX364040B (es) * 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
KR20180100869A (ko) * 2017-03-02 2018-09-12 영진약품 주식회사 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법
CN107080741A (zh) * 2017-04-28 2017-08-22 北京工业大学 吡非尼酮缓释制剂及制备方法
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
EP3511001B1 (en) 2018-01-12 2021-09-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Pirfenidone-containing tablet and capsule formulation
BR112020021412A8 (pt) 2018-04-23 2022-07-05 Taiwan Liposome Co Ltd Composição lipossômica, inalável de liberação prolongada para uso no tratamento de doenças pulmonares
WO2020115774A1 (en) * 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
KR102199415B1 (ko) 2019-02-18 2021-01-06 충북대학교 산학협력단 중합체 및 채널링제를 포함하는 피르페니돈 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제
MX2022012986A (es) * 2020-04-14 2023-03-21 Excalibur Pharmaceuticals Inc Pirfenidona para el tratamiento del coronavirus.
WO2021215856A1 (ko) * 2020-04-22 2021-10-28 영진약품 주식회사 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
DE2366349C2 (de) 1972-12-18 1986-03-27 Affiliated Medical Research Inc., Princeton, N.J. Verfahren zur Herstellung von 5-Methyl-1-phenyl-2-(1H)-pyridon
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
JPS51128438A (en) 1975-04-26 1976-11-09 Yamanouchi Pharmaceut Co Ltd An antibacterial drug against fish diseases
SE430609B (sv) 1976-12-21 1983-11-28 Sca Development Ab Sett att ur cellulosaderivat framstella absorberande material
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
SU1719047A1 (ru) * 1989-11-09 1992-03-15 Воронежский инженерно-строительный институт Вибрационный гранул тор
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
CZ293747B6 (cs) 1995-12-21 2004-07-14 Pfizer Inc. Vodný farmaceutický roztok vhodný pro injekční podávání hostiteli a jeho použití
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
CA2322994A1 (en) 1998-03-17 1999-09-23 Solomon B. Margolin Topical antiseptic compositions and methods
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
DE69810518D1 (de) 1998-09-18 2003-02-06 Mepha Ag Aesch Topisch verabreichbare alkyl-, phenyl-pyridone-arzneimittel
US6277407B1 (en) * 1998-11-10 2001-08-21 Frederick S. Marius Apparatus and method for tablet fabrication
HUP0104606A3 (en) * 1998-12-18 2003-01-28 Basf Ag A pharmaceutical mixture comprising a profen
IN191090B (sr) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
EP1356816B1 (en) * 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
WO2004073713A1 (ja) 2003-02-21 2004-09-02 Shionogi & Co., Ltd. ピルフェニドンのゲル剤
EP1638625A4 (en) 2003-05-23 2009-08-19 David M Ott ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
CA2631497C (en) 2005-12-05 2014-04-22 Bioartificial Gel Technologies Inc. Emulsions of a protein-crosslinked hydrogel matrix and dispersed hydrophobic phase
US20080050449A1 (en) * 2006-03-21 2008-02-28 Dafna Arieli Controlled release formulation of tolterodine
ATE533486T1 (de) * 2006-06-15 2011-12-15 Shanghai Genomics Inc Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
ATE506060T1 (de) * 2006-12-18 2011-05-15 Intermune Inc Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten
JP2010520194A (ja) 2007-03-02 2010-06-10 ミロン、タリア 抗癌剤としてのメルカプトプリン誘導体
MX2007006347A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma.
EP2170828B1 (en) * 2007-06-20 2012-11-21 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
CN101244045B (zh) * 2007-12-21 2010-06-30 东华大学 一种零级给药口服控释片剂及其制备方法
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX352342B (es) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos.
MX364040B (es) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Also Published As

Publication number Publication date
DK2907506T1 (en) 2015-10-12
CA2842654A1 (en) 2013-01-24
KR20140057248A (ko) 2014-05-12
PT2907506T (pt) 2018-02-22
US9962374B2 (en) 2018-05-08
US20160287567A1 (en) 2016-10-06
EP2907506B1 (en) 2017-11-15
CO6970587A2 (es) 2014-06-13
KR20160074016A (ko) 2016-06-27
US20180092893A1 (en) 2018-04-05
CY2200005T2 (el) 2016-04-13
ZA201400386B (en) 2015-04-29
CN112386579A (zh) 2021-02-23
MX2011007675A (es) 2012-07-11
PE20141684A1 (es) 2014-11-13
HK1208172A1 (en) 2016-02-26
DK2907506T3 (en) 2018-02-19
AU2012284627A1 (en) 2014-02-27
RU2682177C2 (ru) 2019-03-15
JP2014522861A (ja) 2014-09-08
AR087205A1 (es) 2014-02-26
DE15161929T1 (de) 2015-11-12
BR112014001297B1 (pt) 2021-11-16
WO2013012307A1 (es) 2013-01-24
CN103957892A (zh) 2014-07-30
DOP2014000010A (es) 2014-06-30
RU2014101231A (ru) 2015-08-27
AU2012284627A8 (en) 2014-04-10
US20210386724A1 (en) 2021-12-16
US10383862B2 (en) 2019-08-20
CR20140019A (es) 2014-05-20
SI2907506T1 (en) 2018-03-30
ES2550227T1 (es) 2015-11-05
JP6034380B2 (ja) 2016-11-30
UA114181C2 (uk) 2017-05-10
CA2842654C (en) 2020-09-15
EP2907506A1 (en) 2015-08-19
HUE036511T2 (hu) 2018-07-30
ES2550227T3 (es) 2018-03-16
US11052074B2 (en) 2021-07-06
US11040030B2 (en) 2021-06-22
NO2907506T3 (sr) 2018-04-14
BR112014001297A2 (pt) 2017-02-21
AU2012284627B2 (en) 2017-07-20
HRP20180183T1 (hr) 2018-03-09
US20140296300A1 (en) 2014-10-02
US20200038386A1 (en) 2020-02-06
HUE15161929T1 (hu) 2016-06-28
LT2907506T (lt) 2018-03-12
KR101632332B1 (ko) 2016-06-22
US20190358213A1 (en) 2019-11-28
PL2907506T3 (pl) 2018-07-31
EP2735306A1 (en) 2014-05-28
UY34190A (es) 2013-02-28
ECSP14013160A (es) 2014-02-28
US9408836B2 (en) 2016-08-09
CL2014000131A1 (es) 2014-08-22
CY1119886T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
HK1208172A1 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
IL267980B (en) A pharmaceutical preparation for the treatment of metabolic syndrome
IL269054A (en) A pharmaceutical preparation containing tesimaltone for use in the treatment of 24-NON
EP2827361A4 (en) FORM, PAINT COATING AND METHOD OF MANUFACTURING THEREFOR AND MICRORELIEF STRUCTURE
IL233663A0 (en) New indolizine compounds, a process for their preparation and pharmaceutical preparations containing them
SG11201401765TA (en) Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
ZA201304709B (en) A pharmaceutical dosage form
IL237138B (en) Pirfenidone for use in a drug given in calculated amounts
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
HK1198814A1 (en) Composite formulation comprising a tablet encapsulated in a hard capsule
TWI559929B (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease
SG11201401770YA (en) Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
PL3067353T3 (pl) Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania
EP2687218A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARATION THEREFOR
HK1189487A1 (zh) 大黃酸在製備治療胰腺纖維化藥物中的應用
GB201700495D0 (en) Method of manufacturing a body adhering absorbent article orientated in the machine direction wih reduced curl
IL213105A (en) Compounds, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
PL2640365T3 (pl) Kompozycja farmaceutyczna zawierająca sól prekursorową cyklu krebsa, zwłaszcza sól cytrynianową, i jej zastosowanie jako leku
IL221747A (en) Inhibits Sodium / Phosphate Co-Transmission through the Aryl Fluorophosphate Peripheral Membrane
AP3344A (en) New dihydro-oxazolobenzodiazepinone compounds, a process for their preparation and pharmaceutical compositions containing them
EP2766369A4 (en) NOVEL SALT OF SITAGLIPTIN, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF
PL2561864T3 (pl) Tabletka powlekana zawierająca tianeptynę i sposób jej otrzymywania
BR112013012652A2 (pt) forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida